Literature DB >> 25170112

What is a true ALCL?

Wolfram Klapper1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25170112      PMCID： PMC4148756          DOI： 10.1182/blood-2014-06-581694

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.

Authors:  Andrew L Feldman; Ahmet Dogan; David I Smith; Mark E Law; Stephen M Ansell; Sarah H Johnson; Julie C Porcher; Nazan Ozsan; Eric D Wieben; Bruce W Eckloff; George Vasmatzis
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

2.  Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1 + with a high content of reactive histiocytes).

Authors:  S Pileri; B Falini; G Delsol; H Stein; P Baglioni; S Poggi; M F Martelli; M T Rivano; D Y Mason; A G Stansfeld
Journal:  Histopathology       Date:  1990-04       Impact factor: 5.087

3.  Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.

Authors:  K Pulford; L Lamant; S W Morris; L H Butler; K M Wood; D Stroud; G Delsol; D Y Mason
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

4.  ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

Authors:  Edgardo R Parrilla Castellar; Elaine S Jaffe; Jonathan W Said; Steven H Swerdlow; Rhett P Ketterling; Ryan A Knudson; Jagmohan S Sidhu; Eric D Hsi; Shridevi Karikehalli; Liuyan Jiang; George Vasmatzis; Sarah E Gibson; Sarah Ondrejka; Alina Nicolae; Karen L Grogg; Cristine Allmer; Kay M Ristow; Wyndham H Wilson; William R Macon; Mark E Law; James R Cerhan; Thomas M Habermann; Stephen M Ansell; Ahmet Dogan; Matthew J Maurer; Andrew L Feldman
Journal:  Blood       Date:  2014-06-03       Impact factor: 22.113

5.  Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.

Authors:  George Vasmatzis; Sarah H Johnson; Ryan A Knudson; Rhett P Ketterling; Esteban Braggio; Rafael Fonseca; David S Viswanatha; Mark E Law; N Sertac Kip; Nazan Ozsan; Stefan K Grebe; Lori A Frederick; Bruce W Eckloff; E Aubrey Thompson; Marshall E Kadin; Dragana Milosevic; Julie C Porcher; Yan W Asmann; David I Smith; Irina V Kovtun; Stephen M Ansell; Ahmet Dogan; Andrew L Feldman
Journal:  Blood       Date:  2012-08-01       Impact factor: 22.113
  5 in total
  2 in total

1.  Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements.

Authors:  Rebecca L King; Linda N Dao; Ellen D McPhail; Elaine S Jaffe; Jonathan Said; Steven H Swerdlow; Christopher A Sattler; Rhett P Ketterling; Jagmohan S Sidhu; Eric D Hsi; Shridevi Karikehalli; Liuyan Jiang; Sarah E Gibson; Sarah L Ondrejka; Alina Nicolae; William R Macon; Surendra Dasari; Edgardo Parrilla Castellar; Andrew L Feldman
Journal:  Am J Surg Pathol       Date:  2016-01       Impact factor: 6.394

2.  Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Authors:  Rebecca A Luchtel; Surendra Dasari; Naoki Oishi; Martin Bjerregård Pedersen; Guangzhen Hu; Karen L Rech; Rhett P Ketterling; Jagmohan Sidhu; Xueju Wang; Ryohei Katoh; Ahmet Dogan; N Sertac Kip; Julie M Cunningham; Zhifu Sun; Saurabh Baheti; Julie C Porcher; Jonathan W Said; Liuyan Jiang; Stephen Jacques Hamilton-Dutoit; Michael Boe Møller; Peter Nørgaard; N Nora Bennani; Wee-Joo Chng; Gaofeng Huang; Brian K Link; Fabio Facchetti; James R Cerhan; Francesco d'Amore; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2018-08-09       Impact factor: 22.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.